How does Cns Pharmaceuticals Inc (CNSP) change from a tortoise to a hare?

With 6.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.58 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.1589 whereas the lowest price it dropped to was $0.1406. The 52-week range on CNSP shows that it touched its highest point at $137.50 and its lowest point at $0.10 during that stretch. It currently has a 1-year price target of $0.50. Beta for the stock currently stands at 1.05.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CNSP was up-trending over the past week, with a rise of 26.17%, but this was up by 11.93% over a month. Three-month performance dropped to -85.49% while six-month performance fell -98.51%. The stock lost -99.84% in the past year, while it has lost -99.75% so far this year. A look at the trailing 12-month EPS for CNSP yields -128.91 with Next year EPS estimates of -0.85.

Float and Shares Shorts:

At present, 33.45 million CNSP shares are outstanding with a float of 32.84 million shares on hand for trading. On 2024-09-30, short shares totaled 0.68 million, which was 211.0 higher than short shares on 1724976000. In addition to Mr. John Michael Climaco Esq., J.D. as the firm’s CEO, President & Director, Mr. Christopher S. Downs CPA, CTP, FP&A serves as its Chief Financial Officer.

Institutional Ownership:

Through their ownership of 0.00448 of CNSP’s outstanding shares, institutional investors have minority control over the company.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, CNSP reported revenue of $0.0 and operating income of -$2528135.0. The EBITDA in the recently reported quarter was -$2525538.0 and diluted EPS was -$6.72.